Literature DB >> 11205725

Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.

L J Lesko1, M Rowland, C C Peck, T F Blaschke.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 11205725     DOI： 10.1023/a:1007574217260

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


× No keyword cloud information.
  12 in total

Review 1.  Simulation of clinical trials.

Authors:  N H Holford; H C Kimko; J P Monteleone; C C Peck
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

2.  Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.

Authors:  C C Peck; W H Barr; L Z Benet; J Collins; R E Desjardins; D E Furst; J G Harter; G Levy; T Ludden; J H Rodman
Journal:  Clin Pharmacol Ther       Date:  1992-04       Impact factor: 6.875

Review 3.  Econometrics in outcomes research: the use of instrumental variables.

Authors:  J P Newhouse; M McClellan
Journal:  Annu Rev Public Health       Date:  1998       Impact factor: 21.981

4.  Pharmacologically guided phase I clinical trials based upon preclinical drug development.

Authors:  J M Collins; C K Grieshaber; B A Chabner
Journal:  J Natl Cancer Inst       Date:  1990-08-15       Impact factor: 13.506

5.  An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche.

Authors:  B G Reigner; P E Williams; I H Patel; J L Steimer; C Peck; P van Brummelen
Journal:  Clin Pharmacokinet       Date:  1997-08       Impact factor: 6.447

6.  Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

Authors:  R Bruno; D Hille; A Riva; N Vivier; W W ten Bokkel Huinnink; A T van Oosterom; S B Kaye; J Verweij; F V Fossella; V Valero; J R Rigas; A D Seidman; B Chevallier; P Fumoleau; H A Burris; P M Ravdin; L B Sheiner
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

7.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

8.  Pharmacokinetics, pharmacodynamics, and rational opioid selection.

Authors:  S L Shafer; J R Varvel
Journal:  Anesthesiology       Date:  1991-01       Impact factor: 7.892

9.  The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers.

Authors:  T D Egan; H J Lemmens; P Fiset; D J Hermann; K T Muir; D R Stanski; S L Shafer
Journal:  Anesthesiology       Date:  1993-11       Impact factor: 7.892

10.  Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B).

Authors:  P S Glass; D Hardman; Y Kamiyama; T J Quill; G Marton; K H Donn; C M Grosse; D Hermann
Journal:  Anesth Analg       Date:  1993-11       Impact factor: 5.108
View more
  20 in total

Review 1.  Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.

Authors:  Jenny Y Chien; Stuart Friedrich; Michael A Heathman; Dinesh P de Alwis; Vikram Sinha
Journal:  AAPS J       Date:  2005-10-07       Impact factor: 4.009

2.  Model-based drug development: the road to quantitative pharmacology.

Authors:  Liping Zhang; Vikram Sinha; S Thomas Forgue; Sophie Callies; Lan Ni; Richard Peck; Sandra R B Allerheiligen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-13       Impact factor: 2.745

3.  Predicting brain concentrations of drug using positron emission tomography and venous input: modeling of arterial-venous concentration differences.

Authors:  Stina Syvänen; Gunnar Blomquist; Lieuwe Appel; Margareta Hammarlund-Udenaes; Bengt Långström; Mats Bergström
Journal:  Eur J Clin Pharmacol       Date:  2006-08-08       Impact factor: 2.953

4.  Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.

Authors:  Karl Brendel; Emmanuelle Comets; Céline Laffont; Christian Laveille; France Mentré
Journal:  Pharm Res       Date:  2006-08-12       Impact factor: 4.200

Review 5.  Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.

Authors:  Karl Brendel; Céline Dartois; Emmanuelle Comets; Annabelle Lemenuel-Diot; Christian Laveille; Brigitte Tranchand; Pascal Girard; Céline M Laffont; France Mentré
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 6.  Integrated pharmacokinetics and pharmacodynamics in drug development.

Authors:  Jasper Dingemanse; Silke Appel-Dingemanse
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator.

Authors:  Xin Zhang; Karen Schneck; Juliana Bue-Valleskey; Kwee Poo Yeo; Michael Heathman; Vikram Sinha
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-12-22       Impact factor: 2.745

8.  Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies.

Authors:  Stefan S De Buck; Annamaria Jakab; Markus Boehm; Douglas Bootle; Dejan Juric; Cornelia Quadt; Timothy K Goggin
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

9.  Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.

Authors:  Shinji Yamazaki
Journal:  AAPS J       Date:  2012-12-19       Impact factor: 4.009

10.  Modeling NSCLC progression: recent advances and opportunities available.

Authors:  Ahmed Abbas Suleiman; Lucia Nogova; Uwe Fuhr
Journal:  AAPS J       Date:  2013-02-13       Impact factor: 4.009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.